Thrombolytic therapy with non-immunogenic staphylokinase in an extended therapeutic window for ischemic stroke. (A single-center experience)

Objective. To evaluate in-hospital outcomes of non-immunogenic staphylokinase as thrombolytic therapy for ischemic stroke administered within a 4.5—9 hour therapeutic window or in cases of unknown onset time (wake-up stroke).. Material and methods. Patients with ischemic stroke within a 4.5—9-hour therapeutic window or with unknown onset time were included retrospectively and prospectively. Staged reperfusion therapy was an exclusion criterion. Neurological deficit severity and functional status were assessed using the National Institutes of Health Stroke Scale (NIHSS) and the modified Rankin Scale (mRS). Results. Fifty patients were included in the study. A favorable functional outcome (mRS 0—2) at discharge was achieved in 54% of patients. Symptomatic hemorrhagic transformation occurred in 2% of cases, and in-hospital mortality was 6%. Conclusion. The findings indicate that thrombolysis with non-immunogenic staphylokinase administered within an extended therapeutic window is an effective and safe reperfusion therapy for ischemic stroke.